Evidence map›Paper›PMID 39448669›Full record

ArticleNPJ Parkinson's disease2024

CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants.

Stefanie Lerche, Isabel Wurster, Enza Maria Valente, Micol Avenali, Daniela Samaniego, Marta Martínez-Vicente, Jorge Hernández-Vara, Ariadna Laguna, Andrea Sturchio, Per Svenningsson and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefanie LercheCenter of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Isabel WursterCenter of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Enza Maria ValenteDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Micol AvenaliIRCCS Mondino Foundation, Pavia, Italy.
Daniela SamaniegoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Marta Martínez-VicenteNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Jorge Hernández-VaraNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Ariadna LagunaNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Andrea SturchioDepartment of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Nicholas P FranceESCAPE Bio, South San Francisco, CA, USA.
Carrolee BarlowESCAPE Bio, South San Francisco, CA, USA.
Sethu SankaranarayananESCAPE Bio, South San Francisco, CA, USA.
Kathrin BrockmannCenter of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. kathrin.brockmann@uni-tuebingen.de.

Funding

Deutsches Zentrum für Neurodegenerative Erkrankungen (German Center for Neurodegenerative Diseases) PD Research, MiGAp study
6 · The paper itself

Abstract

Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF d18:1 sphingolipid species in a longitudinal multicenter cohort comprising people with Parkinson's Disease and Dementia with Lewy bodies with and without GBA1 variants and healthy controls. We found no increase of sphingolipid species in heterozygous GBA1 variant participants and no effect on development of cognitive impairment. Thus, CSF d18:1 sphingolipids are not suitable as state markers in Parkinson's Disease.

Identifiers

PMID39448669
PMCPMC11502890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.